Showing results (61-70 of 160) with videos related to

Sort By:
Pageof 16
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 2, 2021
Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound?Johanna Weiss, Kathrin Isabelle Foerster, Maria Weber, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 4, 2021
A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactionsSebastian Frechen, Juri Solodenko, Thomas Wendl, et al.
Pharmaceutics|June 21, 2020
A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug-Drug Interaction StudiesNina Hanke, Denise Türk, Dominik Selzer, et al.
Clinical Pharmacokinetics|May 27, 2019
Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and ItraconazoleDenise Türk, Nina Hanke, Sarah Wolf, et al.
European Journal of Clinical Pharmacology|April 14, 2007
Tadalafil population pharmacokinetics in patients with erectile dysfunctionIñaki F Trocóniz, Christiane Tillmann, Alexander Staab, et al.
Biopharmaceutics & Drug Disposition|September 23, 2009
Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype ratsSilke Retlich, Barbara Withopf, Andreas Greischel, et al.
JAMA Internal Medicine|September 2, 2025
Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical TrialThorsten Lehr, Peter Meiser, Dominik Selzer, et al.
Cancer Chemotherapy and Pharmacology|October 9, 2017
A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specificationDaniel Moj, Hannah Britz, Jürgen Burhenne, et al.
Pharmaceutics|September 28, 2021
External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel DiseaseChristina Schräpel, Lukas Kovar, Dominik Selzer, et al.
Clinical Pharmacokinetics|March 14, 2020
Comprehensive Parent-Metabolite PBPK/PD Modeling Insights into Nicotine Replacement Therapy StrategiesLukas Kovar, Dominik Selzer, Hannah Britz, et al.
Pageof 16